Stock Analysis on Net

Allergan PLC (NYSE:AGN)

$22.49

This company has been moved to the archive! The financial data has not been updated since May 7, 2020.

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Allergan PLC, common-size consolidated balance sheet: liabilities and stockholders’ equity

Microsoft Excel
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Accrued third-party rebates
Litigation-related reserves and legal fees
Accrued payroll and related benefits
Accrued returns and other allowances
Accrued R&D expenditures
Interest payable
Royalties payable
Accrued pharmaceutical fees
Accrued severance, retention and other shutdown costs
Accrued non-provision taxes
Accrued selling and marketing expenditures
Current portion of contingent consideration obligations
Dividends payable
Other accrued expenses
Accrued expenses
Accounts payable
Accounts payable and accrued expenses
Income taxes payable
Current portion of long-term debt and capital leases
Current portion of lease liability, operating
Current liabilities held for sale
Current liabilities
Long-term debt and capital leases, excluding current portion
Lease liability, operating, excluding current portion
Acquisition related contingent consideration liabilities
Long-term pension and post retirement liability
Legacy Allergan deferred executive compensation
Accrued R&D milestone
Long-term contractual obligations
Deferred revenue
Product warranties
Long-term severance and restructuring liabilities
Other long-term liabilities
Other long-term liabilities
Long-term liabilities held for sale
Other taxes payable
Deferred tax liabilities
Long-term liabilities
Total liabilities
Preferred shares, $0.0001 par value per share
Ordinary shares; $0.0001 par value per share
Additional paid-in capital
Retained earnings
Accumulated other comprehensive income (loss)
Shareholders’ equity
Noncontrolling interest
Total equity
Total liabilities and equity

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).


Accrued third-party rebates
There is a consistent upward trend from 0.94% in 2015 to 2.11% in 2019, indicating increasing rebates liabilities relative to total liabilities and equity.
Litigation-related reserves and legal fees
These liabilities remain low and stable between 0.07% and 0.16% until 2018, then spike significantly to 1.32% in 2019, suggesting emerging or resolved legal matters impacting liability.
Accrued payroll and related benefits
A steady increase from 0.30% in 2015 to 0.88% in 2019 implies growing payroll-related obligations relative to the company's total liabilities and equity.
Accrued returns and other allowances
This component more than doubles from 0.21% in 2015 to 0.63% in 2019, indicating higher anticipated product returns or other allowances.
Accrued R&D expenditures
There is a decrease from 0.28% in 2015 to 0.12% in 2016, followed by slight fluctuations and a stable level near 0.20% in 2018-2019, suggesting relatively stable R&D accrual patterns in recent years.
Interest payable
This liability remains quite stable, fluctuating narrowly around 0.20% across the years, indicating consistent interest obligations relative to total liabilities and equity.
Royalties payable
There is an increase from 0.09% in 2015 to 0.23% in 2019, demonstrating growing royalty-related liabilities.
Accrued pharmaceutical fees
These fees remain relatively stable between 0.12% and 0.17%, with a slight downward trend toward 0.13% in 2019.
Accrued severance, retention, and other shutdown costs
The trend is downward, starting at 0.08% in 2015 and diminishing to 0.01% in 2019, possibly reflecting reduced restructuring activities.
Accrued non-provision taxes
Values are low and stable around 0.07% across the periods, indicating consistent tax accruals without significant changes.
Accrued selling and marketing expenditures
There is a decrease from 0.09% in 2015 to 0.04% in 2017, stabilizing at 0.06% subsequently, suggesting relative control over selling and marketing expenses accrued.
Current portion of contingent consideration obligations
This fluctuates significantly, peaking at 0.40% in 2016, then declining to 0.01% in 2018-2019. This pattern may indicate settlement or revaluation of contingent liabilities over time.
Dividends payable
Dividends payable disappear after 2017, with zero values recorded in 2018 and 2019, which could suggest a change in dividend policy or timing.
Other accrued expenses
There is a sharp increase to 1.01% in 2017 from 0.27% in 2015, followed by a decrease to 0.43% in 2019, indicating some volatility in miscellaneous accrued expenses.
Accrued expenses
Overall, accrued expenses rise steadily from 2.93% in 2015 to 6.29% in 2019, reflecting growing short-term liabilities relative to total liabilities and equity.
Accounts payable
This item fluctuates, decreasing in 2016 to 0.17%, then increasing to 0.41% by 2019, showing variability in payables management or trading terms.
Accounts payable and accrued expenses
A consistent upward trend is observed, growing from 3.20% in 2015 to 6.70% in 2019, reinforcing the increase seen in accrued expenses and accounts payable combined.
Income taxes payable
Slight increases are noted, moving from 0.04% in 2015 to 0.07% by 2018 and 2019, showing modest growth in tax liabilities.
Current portion of long-term debt and capital leases
This line increases overall from 1.79% in 2015 to 4.79% in 2019, with a dip in 2018. The rise indicates increasing short-term debt obligations or reclassification of debt portions.
Current portion of lease liability, operating
Data is only available for 2019 at 0.13%, indicating a new lease liability item likely introduced due to accounting changes.
Current liabilities held for sale
Present only in 2015 at 1.10%, implying a one-time classification of liabilities related to assets held for sale that disappears afterward.
Current liabilities (total)
The ratio shows a decrease from 6.13% in 2015 to 5.63% in 2018, then markedly increases to 11.69% in 2019, indicating a substantial increase in short-term obligations in the latest year.
Long-term debt and capital leases, excluding current portion
There is a declining trend from 29.66% in 2015 to 19.13% in 2019, suggesting a reduction in long-term debt relative to total liabilities and equity.
Lease liability, operating, excluding current portion
Reported only in 2019 at 0.47%, evidencing new recognition of lease liabilities potentially due to updated accounting standards.
Acquisition related contingent consideration liabilities
These liabilities decline from 0.58% in 2015 to 0.33% in 2018, then slightly increase to 0.40% in 2019, indicating some fluctuation in contingent obligations tied to acquisitions.
Long-term pension and post-retirement liability
Relatively stable near 0.15%, with minimal variation, suggesting consistent valuation and funding of pension obligations.
Legacy Allergan deferred executive compensation
This liability remains steady at approximately 0.09%-0.10%, signaling stable deferred compensation obligations.
Accrued R&D milestone
Identified only from 2018 onwards at around 0.07%-0.08%, showing recognition of accruals linked to R&D milestones achieved or expected.
Long-term contractual obligations
Small values between 0.02% and 0.04% are recorded, indicating minor long-term contractual liabilities relative to total liabilities and equity.
Deferred revenue
A slight increase is seen from 0.01% in 2015 to 0.04% in 2018, then a small decline to 0.03% in 2019, demonstrating relatively minor but consistent deferred revenue accruals.
Product warranties
Stable at around 0.02%-0.03%, indicating a regular provision for warranty-related liability.
Long-term severance and restructuring liabilities
These liabilities are minimal and variable, remaining below 0.04% and decreasing to 0.01% by 2019, reflecting limited restructuring obligations.
Other long-term liabilities
Reported twice with differing values: one set between 0.02% to 0.09%, another between 0.75% and 0.93%. Both sets show minor fluctuations, collectively suggesting small miscellaneous long-term liabilities.
Long-term liabilities held for sale
Only present in 2015 at 0.43%, indicating a one-time event of liabilities classified as held for sale.
Other taxes payable
There is a clear rising trend from 0.59% in 2015 to 1.80% in 2019, suggesting increasing tax-related liabilities outside of income taxes.
Deferred tax liabilities
Peaking at 10.05% in 2016 before declining steadily to 4.61% in 2019, indicating a significant reduction in deferred tax obligations after 2016.
Long-term liabilities (total)
This figure decreases from 37.49% in 2015 to 26.86% in 2019, reflecting an overall reduction in long-term obligations relative to total liabilities and equity.
Total liabilities
Total liabilities decrease from 43.62% in 2015 to 36.01% in 2018 before increasing to 38.55% in 2019, showing an overall declining trend with a slight reversal in the latest year.
Preferred shares
The percentage increases slightly from 3.63% in 2015 to 4.17% in 2017, then data is absent for subsequent years, suggesting possible redemption or reclassification after 2017.
Additional paid-in capital
A decline from 50.43% in 2015 to 41.83% in 2016 is followed by a steady increase reaching 59.11% in 2019, indicating growth in paid-in capital over time.
Retained earnings
Significant fluctuation occurs with a peak at 14.22% in 2016, followed by a steep decrease to 1.05% in 2019, suggesting variability in profit retention and dividend policies.
Accumulated other comprehensive income (loss)
This item moves from negative values in 2015 and 2016 to positive amounts from 2017 onward, stabilizing around 1.27%, indicating improved comprehensive income excluding net earnings.
Shareholders’ equity
There is a growth trend from 56.38% in 2015 to a peak of 63.97% in 2018, with a slight decline to 61.43% in 2019, indicating an overall strengthening of equity relative to total liabilities and equity.
Noncontrolling interest
Remains negligible but slightly positive from 2016 onward, suggesting minimal ownership stakes by outside parties.
Total equity
Follows a similar pattern to shareholders’ equity, increasing from 56.38% in 2015 to 63.99% in 2018, and then declining slightly to 61.45% in 2019.
Total liabilities and equity
Consistently at 100% by definition, serving as the base for all other percentage analyses.